Advertisement

Antidiabetika

  • Hans-Georg Joost
  • Klaus Mengel

Zusammenfassung

Die Arzneitherapie des Diabetes mellitus hat in den letzten zehn Jahren stetig zugenommen. Die Insulinverordnungen haben sich in diesem Zeitraum mehr als verdoppelt. Die Biguanidverordnungen sind sogar etwa sechsfach angestiegen, während die der Sulfonylharnstoffe annähernd konstant geblieben sind.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (2002): Glaskörper-und Retinablutungen unter Insulin glargin. Dtsch. Ärztebl. 99: C680.Google Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (2002a): Arzneiverordnungen in der Praxis: Diabetes mellitus.Google Scholar
  3. Bailey CJ, Path MRC, Turner RC (1996): Metformin. N Engl J Med 334: 574–579.PubMedCrossRefGoogle Scholar
  4. Berger M, Köbberling J, Windeler J (1996): Wirksamkeit und Wertigkeit der Acarbose. Dtsch Ärztebl 93: B-443–444.Google Scholar
  5. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW et al. (1994): The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928–935.PubMedGoogle Scholar
  6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for the STOP-NIDDM Trail Research Group (2002): Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077.PubMedCrossRefGoogle Scholar
  7. Damsbo P, Clausen P, Marbury TC, Windfeld K (1999): A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789–794.PubMedCrossRefGoogle Scholar
  8. De Fronzo RA, Goodman M (1995): Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541–549.CrossRefGoogle Scholar
  9. Diabetes Control and Complications Trial Research Group (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.CrossRefGoogle Scholar
  10. Diamant M, Heine RJ (2003): Thiazolidinediones in type 2 diabetes mellitus. Drugs 63:1373–1405.PubMedCrossRefGoogle Scholar
  11. Dills DG, Schneider J (1996): Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 28:426–429.PubMedCrossRefGoogle Scholar
  12. Draeger KE, Wernicke-Panten K, Lomp H-J, Schüler E, Roßkamp R (1996): Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 28:419–425.PubMedCrossRefGoogle Scholar
  13. Dunn CJ, Peters DH (1995): Metformin — A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49: 721–749.PubMedCrossRefGoogle Scholar
  14. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ (2003): Insulin Glargine. An updated review of its use in the management of diabetes mellitus. Drugs 63: 1743–1778.PubMedCrossRefGoogle Scholar
  15. Everett J, Kerr D (1994): Changing from porcine to human insulin. Drugs 47:286–296.PubMedCrossRefGoogle Scholar
  16. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A et al. (2001): Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24: 151–158.PubMedCrossRefGoogle Scholar
  17. Gale EAM for the UK Trial Group (2000): A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. Diabetic Med 17:209–214.CrossRefGoogle Scholar
  18. Gulliford M, Latinovic R (2004): Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239–245.PubMedCrossRefGoogle Scholar
  19. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004): Acarbose reduziert das Risiko für einen Myocardinfarkt bei Typ 2 Diabetikern: Metaanalyse von sieben Langzeitstudien. European Heart Journal 25:10–16.PubMedCrossRefGoogle Scholar
  20. Heinemann L, Heise T (2001): Klinische Wirkungen und Pharmakodynamik der Insulinanaloga lispro, aspart und glargin. Dtsch Med Wschr 126: 597–604.PubMedCrossRefGoogle Scholar
  21. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000): Timeaction profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649.PubMedCrossRefGoogle Scholar
  22. Hollander PA, Zheng H, Schwartz SL, Foley JE, Gatlin MR, Dunning BE, Haas SJ (2001): Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24: 983–988.PubMedCrossRefGoogle Scholar
  23. Holman RR, Mayon White V, Orde-Peckar C, Steemson J, Smith B et al. (1983): Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet: 204–208.Google Scholar
  24. Holman RR, Cull CA, Turner RC (1999): A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K). Prospective Diabetes Study 44). Diabetes Care 22: 960–964.PubMedCrossRefGoogle Scholar
  25. Holstein A, Plaschke A, Egberts EH (2001): Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473.PubMedCrossRefGoogle Scholar
  26. Holstein A, Plaschke A, Hammer C, Egberts EH (2003): Characteristics and time course of severe glimepiride versus glibenclamide-induced hypoglycemia. Eur J Clin Pharmacol 59: 91–97.PubMedCrossRefGoogle Scholar
  27. Home PD, Lindholm A, Riis A (2000): Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 17: 762–770.PubMedCrossRefGoogle Scholar
  28. Karam JH, Etzwiler DD (eds.) (1983): International Symposium on human insulin. Diabetes Care 6:1–68.Google Scholar
  29. Koivisto VA (1998): The human insulin analogue insulin lispro. Ann Med 30:260–266.PubMedCrossRefGoogle Scholar
  30. Lalli C, Ciofetta M, del Sindaco P, Torlone E, Pampanelli S et al. (1999): Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22: 468–477.PubMedCrossRefGoogle Scholar
  31. Landgraf R, Bilo HJ, Müller PG (1999): A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55:165–171.PubMedCrossRefGoogle Scholar
  32. Landgraf R, Frank M, Bauer C, Dieken ML (2000): Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obes Relat Metab Disord 24(Suppl. 3): S38–S44.PubMedCrossRefGoogle Scholar
  33. Langtry HD, Balfour JA (1998): Glimepiride. A review of its use in the management of Type 2 diabetes mellitus. Drugs 55: 563–584.PubMedCrossRefGoogle Scholar
  34. Laube H (2002): Acarbose. An update of its therapeutic use in diabetes treatment. Clin Drug Invest 22:141–156.CrossRefGoogle Scholar
  35. Marbury T, Huang WC, Strange P, Lebovitz H (1999): Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43:155–166.PubMedCrossRefGoogle Scholar
  36. McCall AL (2001): Clinical review of glimepiride. Expert Opin Pharmacother 2: 699–713.PubMedCrossRefGoogle Scholar
  37. Moses R (2000): A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 1: 1455–1467.PubMedCrossRefGoogle Scholar
  38. Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A et al. (2000): Increased mortality in type 2 diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43: 558–560.PubMedCrossRefGoogle Scholar
  39. Rosenstock J, Samols E, Muchmore DB, Schneider J (1996): Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19:1194–1199.CrossRefGoogle Scholar
  40. Scheen AJ (2003): Is there a role for alpha-Glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs 63: 933–951.PubMedCrossRefGoogle Scholar
  41. Scheen AJ, Lethiexhe MR, Lefebvre PJ (1999): Minimal influence of the time interval between injection of regulär insulin and food intake on blood glucose control of Type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 25: 157–162.PubMedGoogle Scholar
  42. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE et al. (2000): Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321:405–412.PubMedCrossRefGoogle Scholar
  43. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995): Metabolie effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550–554.PubMedCrossRefGoogle Scholar
  44. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H et al. for the Finnish Diabetes Prevention Study Group (2001): Prevention of type 2 diabetes mellitus by changes in lifestyle among subjeets with impaired glucose tolerance. N Engl J Med 344:1343–1350.PubMedCrossRefGoogle Scholar
  45. UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive glood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853.CrossRefGoogle Scholar
  46. UK Prospective Diabetes Study (UKPDS) Group (1998b): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.CrossRefGoogle Scholar
  47. Veneman TF, Tack CJ, van Haeften TW (1998): The newly developed sulfonylurea glimepiride: a new ingredient, an old reeipe. Neth J Med 52:179–186.PubMedCrossRefGoogle Scholar
  48. Wagstaff AJ, Goa KL (2002): Rosiglitazone: A review of its use in the management of type 2 diabetes. Drugs 62:1805–1837.PubMedCrossRefGoogle Scholar
  49. Wilde MI, McTavish D (1997): Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54: 597–614.PubMedCrossRefGoogle Scholar
  50. Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study Group (1999): A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22: 463–467.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Hans-Georg Joost
    • 1
  • Klaus Mengel
    • 2
  1. 1.Deutsches Institut für ErnährungsforschungBergholz-Rehbrücke
  2. 2.Mannheim

Personalised recommendations